Capnia Inc(NASDAQ:CAPN) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.16.
In a different note, On Jan 26, 2017, Maxim Group said it Upgrades its rating on Capnia Inc. In the research note, the firm Announces the price-target to $5 per share. The shares have been rated ‘Buy’ by the firm.
Capnia Inc (CAPN) shares turned negative on Fridays trading session with the shares closing down -0.0802 points or -10.38% at a volume of 89,000. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.7594. The peak price level was also seen at $0.7594 while the days lowest was $0.6923. Finally the shares closed at $0.6923. The 52-week high of the shares is $1.57 while the 52-week low is $0.55. According to the latest information available, the market cap of the company is $33 M.
Several Insider Transactions has been reported to the SEC. On Aug 22, 2016, Bhatnagar Anish (director officer ) purchased 10,000 shares at $0.96 per share price.Also, On Aug 19, 2016, David D O’toole (officer ) purchased 2,000 shares at $1.01 per share price.On Aug 19, 2016, Ernest Mario (director 10% owner) purchased 48,806 shares at $1.19 per share price, according to the Form-4 filing with the securities and exchange commission.
Capnia Inc. develops medical diagnostics and therapeutics based on its technology for precision metering of gas flow. The Company’s diagnostic product CoSense aids in the diagnosis of hemolysis in neonates. The Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze Technology Platform a portfolio of methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath. The Company’s therapeutic technology involves the use of metered nasal carbon dioxide (CO2) for the potential treatment of various diseases. Serenz is the Company’s allergy therapeutic product candidate. It also launched new initiatives for the development of this technology for the treatment of trigeminally mediated pain disorders such as cluster headache and trigeminal neuralgia.